Skip to Main Content
Skip Nav Destination

Nelson's Pediatric Antimicrobial Therapy Updates

July 29, 2022

The following updates have been issued for 2022 Nelson's Pediatric Antimicrobial Therapy, 28th Edition:

 

AAP Interim COVID-19 Guidance

Because interim COVID guidance continues to evolve at a rapid pace (including potential new therapeutics), we are adding a link to the AAP COVID-19 guidance page (www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/).

 

Ceftolozane/Tazobactam Receives FDA Approval

Ceftolozane/tazobactam was approved by the FDA in April 2022 for all pediatric and adolescent age-groups from birth up to 18 years. Ceftolozane is more active than some of the other antipseudomonal cephalosporins, ceftazidime and cefepime, against Pseudomonas aeruginosa, including some strains that are meropenem resistant. Ceftolozane is also active against most enteric bacilli (eg, Escherichia coli, Klebsiella, Enterobacter), similar to ceftriaxone but with stability to the ampC beta-lactamases that inactivate ceftriaxone and ceftazidime. Ceftolozane is paired with tazobactam (a beta-lactamase inhibitor that has been available with piperacillin for several years), allowing for additional activity against ESBL-producing enteric bacilli but lacking stability to carbapenemases. Although the anaerobic spectrum is quite reasonable, ceftolozane/tazobactam was paired with metronidazole in the initial adult studies for complicated intra-abdominal infection that were designed by Cubist Pharmaceuticals for FDA approval. These adult studies succeeded, so pediatric studies used the same clinical trial design.

Following are the FDA package label indications for pediatrics: complicated intra-abdominal infections, used in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis. Pediatric studies for nosocomial pneumonia, sponsored by Merck, are ongoing.

 


image of yellow book cover for 2022 Nelson's Pediatric Antimicrobial Therapy

2022 Nelson's Pediatric Antimicrobial Therapy, 28th Edition

This best-selling and widely used resource on pediatric antimicrobial therapy provides instant access to reliable, up-to-the-minute recommendations for treatment of infectious diseases in children.

Visit shop.aap.org to order 2022 Nelson’s Pediatric Antimicrobial Therapy, 28th Edition today!

 


 

Available for separate purchase: Nelson’s 2022 app for iOS!

https://apps.apple.com/us/app/nelson-pediatric-abx-2022/id1611269134

Close Modal

or Create an Account

Close Modal
Close Modal